Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Minority Interest (2024 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Minority Interest for 2 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Minority Interest changed 0.0% to $7.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.0 million, a 0.0% change, with the full-year FY2025 number at $7.0 million, changed 0.0% from a year prior.
  • Minority Interest was $7.0 million for Q4 2025 at Ultragenyx Pharmaceutical, roughly flat from $7.0 million in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $7.0 million in Q3 2024 to a low of $7.0 million in Q3 2024.